Why is Fevertree stock sliding today?

Fever-Tree shares fell 6.4% to 765.5p despite first-half adjusted EBITDA of £20.1 million and revenue of £184.2 million, both ahead of Jefferies estimates of £19.5 million and £182.2 million, respectively. Investors focused on thin U.S. margins amid elevated marketing spending, while Jefferies left FY2026 revenue and EBITDA forecasts unchanged at £400.7 million and £50.1 million. UK revenue rose 3%, Europe grew 10% constant currency, and the interim dividend increased 2% to 6.09p, but these positives did not offset concerns over the profitability of U.S. expansion.

Analysis

The key issue is not top-line demand but the incremental return on U.S. customer acquisition spending. If U.S. marketing remains elevated without a visible improvement in gross-to-contribution margin conversion, Fever-Tree risks a prolonged valuation discount versus premium branded-beverage peers: revenue growth will be treated as purchased rather than organic. The buyback modestly supports per-share earnings but cannot offset a de-rating if consensus EBITDA estimates remain flat; it also reduces flexibility should the U.S. investment cycle need to be extended.

Near term, the selloff may persist because there is no estimate-revision catalyst before evidence of U.S. margin inflection, likely the next trading update or FY results over the next 3-6 months. European growth provides cash-flow support, but it does not resolve the market's concern that the largest addressable market is dilutive at the margin. Energy hedges reduce one input-cost tail risk, shifting investor focus more directly toward advertising efficiency, distributor economics, and U.S. pricing/mix.

The contrarian case is that current marketing is building distribution and consumer repeat rates that are not visible in interim margins; if management can show stable U.S. gross margin alongside slowing marketing growth, operating leverage could drive an outsized EBITDA upgrade in 2027. That outcome requires independently observable KPIs—U.S. revenue growth, marketing as a percentage of sales, and segment contribution margin—not simply another aggregate revenue beat. JEF has no material read-through beyond its published research view; this is a company-specific FEVR setup.

Key Decisions for Investors

• Maintain a 3-6 month underweight/short bias on FEVR following any rebound toward 830-850p, rather than chase weakness near the 52-week low. Thesis: absent a U.S. margin upgrade, flat FY EBITDA expectations leave downside toward 711p; cover if U.S. profitability KPIs improve or FY EBITDA guidance rises materially.
• For long-only accounts, wait for the next update to establish that U.S. marketing expense is growing slower than U.S. sales and that group EBITDA guidance is raised. A close above roughly 850p on estimate upgrades would be a more credible entry signal than a headline earnings beat.
• Watch U.S. beverage category data and management disclosure on distribution, repeat purchase, and promotional intensity over the next 1-3 months. A broad premium-consumer slowdown would worsen the downside case; conversely, sustained U.S. volume growth with lower promotional intensity would falsify the short thesis.
• Do not use the dividend increase or buyback alone as a catalyst for a long position. Treat capital returns as downside support only; reassess if buyback pace begins competing with necessary U.S. investment or if net-cash conversion deteriorates.